Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00730288 | Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects | PHASE2 | COMPLETED | 35 | — | — | Aug 1, 2006 | Jan 1, 2008 | Feb 27, 2018 | 1 | Australia |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Received monovalent Vero dengue vaccine in Study DIV12 |
| 2 | EXPERIMENTAL | Received Yellow fever vaccine in Study DIV12 |
| 3 | EXPERIMENTAL | Flavivirus-naive subjects |
| Name | Type | Description |
|---|---|---|
| Chimeric dengue serotype (1, 2, 3, 4) | BIOLOGICAL | 0.5 mL, Subcutaneous, 1 dose |
Inclusion Criteria : * Aged 18 to 40 years on the day of inclusion. * Informed consent form signed. * For a woman, inability to bear a child or negative serum pregnancy test. * Completed the one-year follow-up of Study DIV12. * Able to attend all scheduled visits and to comply with all trial proced...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 5 | PHASE3 | Tetravalent Dengue Vaccine, TDV |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | EYU688 |
| Sanofi SA Sponsored ADR | SNY | 1 | — | Undisclosed |
| Abbott Laboratories | ABT | 1 | — | Undisclosed |
| Danaher Corporation | DHR | 1 | — | Undisclosed |